Predicted to have retinyl-palmitate esterase activity and triglyceride lipase activity. Predicted to be involved in several processes, including acylglycerol metabolic process; negative regulation of sequestering of triglyceride; and positive regulation of triglyceride catabolic process. Predicted to localize to several cellular components, including cytosol; lipid droplet; and nucleoplasm. Orthologous to human PNPLA2 (patatin like phospholipase domain containing 2); INTERACTS WITH (+)-catechin; (-)-cotinine; (S)-nicotine.
[Nicotine results in increased abundance of Cotinine] which results in increased expression of PNPLA2 mRNA, [Nicotine results in increased abundance of Cotinine] which results in increased expression of PNPLA2 protein
[Nicotine results in increased abundance of Cotinine] which results in increased expression of PNPLA2 mRNA, [Nicotine results in increased abundance of Cotinine] which results in increased expression of PNPLA2 protein
[Dietary Sucrose co-treated with Dietary Fats co-treated with bisphenol A co-treated with Diethylhexyl Phthalate co-treated with Tetrachlorodibenzodioxin co-treated with 2 more ...
[Dietary Sucrose co-treated with Dietary Fats co-treated with bisphenol A co-treated with Diethylhexyl Phthalate co-treated with Tetrachlorodibenzodioxin co-treated with 2 more ...
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin] results in increased expression of PNPLA2 mRNA
[licarin A affects the susceptibility to [INS protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone]] which results in increased expression of PNPLA2 mRNA more ...
[Dietary Sucrose co-treated with Dietary Fats co-treated with bisphenol A co-treated with Diethylhexyl Phthalate co-treated with Tetrachlorodibenzodioxin co-treated with 2 more ...
[Dietary Sucrose co-treated with Dietary Fats co-treated with bisphenol A co-treated with Diethylhexyl Phthalate co-treated with Tetrachlorodibenzodioxin co-treated with 2 more ...
[MT1 gene mutant form results in increased susceptibility to Cadmium Chloride] which results in decreased expression of PNPLA2 mRNA, [MT2 gene mutant form results in increased susceptibility to Cadmium Chloride] which results in decreased expression of PNPLA2 mRNA
[Clofibrate co-treated with Acetaminophen] affects the expression of PNPLA2 mRNA, PPARA affects the reaction [[Clofibrate co-treated with Acetaminophen] affects the expression of PNPLA2 mRNA]
[licarin A affects the susceptibility to [INS protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone]] which results in increased expression of PNPLA2 mRNA more ...
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin] results in increased expression of PNPLA2 mRNA
Scopoletin inhibits the reaction [Ethanol results in increased expression of PNPLA2 mRNA], Silymarin inhibits the reaction [Ethanol results in increased expression of PNPLA2 mRNA]
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin] results in increased expression of PNPLA2 mRNA
[licarin A affects the susceptibility to [INS protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone]] which results in increased expression of PNPLA2 mRNA more ...
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[licarin A affects the susceptibility to [INS protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone]] which results in increased expression of PNPLA2 protein]
[Nicotine results in increased abundance of Cotinine] which results in increased expression of PNPLA2 mRNA, [Nicotine results in increased abundance of Cotinine] which results in increased expression of PNPLA2 protein
PNPLA2 protein promotes the reaction [resveratrol results in decreased expression of IL6 mRNA], PNPLA2 protein promotes the reaction [resveratrol results in decreased expression of TNF mRNA]
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Gene-Chemical Interaction Annotations
